Key Highlights

  • The stock was up 9.29% to USD 2.00 in pre-market trading on November 3, 2026.
  • The implied Monday close was about USD 1.83 (calculated from the screen move).
  • A 1-for-20 Reverse Stock Split took effect at market open on October 26, 2026.
  • Nasdaq set a January 11, 2027 deadline to regain a closing bid of at least USD 1.00.
  • Revenue for fiscal 2025 was USD 20.3 million, according to market data.

What is moving the shares before the opening bell (up USD 0.1700, 9.29%)

Cellyan Biotechnology (NASDAQ:HKPD) was up 9.29% to USD 2.00 in pre-market trading on November 3, 2026. The move is measured against a Monday November 2, 2026 close of about USD 1.83 (calculated).

The shares began trading on a post-split basis on October 26, 2026, so the quoted price is far higher than the pre-split level of roughly USD 0.15 seen in early September. Market data showed a close of USD 2.19 on October 26, 2026, meaning the stock has since drifted lower before today's bounce.

Was there a catalyst

No company announcement dated October 30 to November 3, 2026 was identified in press releases or regulatory filings. The latest company release found was the October 21, 2026 notice of the reverse split, so this article does not tie the pre-market gain to a specific event.

Following a reverse split, thinly traded shares often move several percent in either direction without news, though that is an inference rather than a confirmed cause.

Business and background

The company, formerly Hong Kong Pharma Digital Technology Holdings Limited, operates two Hong Kong subsidiaries that move over-the-counter pharmaceutical products toward Mainland China-related markets. One handles cross-border E-commerce Supply chain services including storage, packaging and delivery, and the other manages cross-border procurement and distribution.

It listed on the Nasdaq Capital Market on January 15, 2025, selling 1,403,685 shares at USD 4.00 per share. Shareholders approved a name change, a reverse share split and a 2025 Equity incentive plan at the annual meeting held on December 12, 2025.

Balance sheet and risks

The company filed its Annual Report on Form 20-F on August 7, 2026, and market data showed fiscal 2025 Revenue of USD 20.3 million with a net loss of about USD 27,000. On June 12, 2026 it filed a shelf registration for up to USD 200 million of securities, which could lead to dilution if used.

Nasdaq issued a bid price deficiency notice dated January 12, 2026 and on July 16, 2026 granted an additional 180 calendar days, until January 11, 2027. The company has said there is no assurance it will regain or maintain compliance. As a Penny Stock with a Market Value of only a few million dollars, the shares carry heightened volatility, thin Liquidity and dilution risk.

What to watch next

Investors will watch whether the closing bid holds above USD 1.00 for ten consecutive Business days ahead of the January 11, 2027 deadline. Any use of the shelf registration, further Nasdaq correspondence or interim results would also be material.

The regular session on November 3, 2026 will show whether the pre-market gain holds near USD 2.00.